Audentes Therapeutics (BOLD) Tops Q1 EPS by 173c

Audentes Therapeutics (NASDAQ: BOLD) reported Q1 EPS of $0.71, $1.73 better than the analyst estimate of ($1.02).

For earnings history and earnings-related data on Audentes Therapeutics (BOLD) click here.

You May Also Be Interested In

• loanDepot receives NYSE non-compliance notice over stock price
• Myriad Uranium completes acquisition of Rush Rare Metals
• OBOOK Holdings posts $18.8M net loss as OwlPay Harbor volume rises